Shea (Shay)

Shea, a genomics and gene-editing expert, dives into revolutionary CRISPR advancements. The discussion highlights the shift from ex vivo therapies to more efficient in vivo treatments for common conditions like cardiovascular diseases. Shea reveals how lipid nanoparticles could simplify patient experiences with potentially single-dose treatments. They explore the vast market implications and potential savings in healthcare costs, while considering the allure of one-time genetic edits versus ongoing statin use. The future of gene editing holds exciting promise as we rethink treatment paradigms for widespread diseases.